Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP-18-2
- Development stage
- Unknown
- Lead developer
- Nanopharmaceutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NP-18-2 is an orally-bioavailable small molecule drug developed by Nanopharmaceutics, Inc. It is currently in Phase 2 clinical development for Central Nervous System (CNS) disorders. NP-18-2 acts as a selective full agonist of the 5-Hydroxytryptamine receptor 1A (5-HT1A), a ligand and likely agonist for the Sigma-1 receptor, and a selective antagonist of the 5-Hydroxytryptamine receptor 2B (5-HT2B). It also demonstrates selective binding to the Sigma-2 receptor.
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2B (5-Hydroxytryptamine Receptor 2B)SIGMAR1 (Sigma non-opioid intracellular receptor 1)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))
Beyond the preview
Go deeper on NP-18-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP-18-2.